Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
Year: 2021
Type: article
Abstract: OBJECTIVES: In the phase III SOLO1 trial (NCT01844986), maintenance olaparib provided a substantial progression-free survival benefit in patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation who were in response after platinum-based chemotherapy. We analyzed the timing, duration and grade of the most common hematologic and non-hematologic adverse events in SOLO1. METHODS: Eligible patients were randomized to olaparib tablets 300 mg twice daily (N = 260) or placebo (N = 131), with a 2-year treatment cap in most patients. Safety outcomes were analyzed in detail in randomized patients who received at least one dose of study drug (olaparib, n = 260; placebo, n = 130). RESULTS: Median time to first onset of the most common hematologic (anemia, neutropenia, thrombocytopenia) and non-hematologic (nausea, fatigue/asthenia, vomiting) adverse events was <3 months in olaparib-treated patients. The first event of anemia, neutropenia, thrombocytopenia, nausea and vomiting lasted a median of <2 months and the first event of fatigue/asthenia lasted a median of 3.48 months in the olaparib group. These adverse events were manageable with supportive treatment and/or olaparib dose modification in most patients, with few patients requiring discontinuation of olaparib. Of 162 patients still receiving olaparib at month 24, 64.2% were receiving the recommended starting dose of olaparib 300 mg twice daily. CONCLUSIONS: Maintenance olaparib had a predictable and manageable adverse event profile in the newly diagnosed setting with no new safety signals identified. Adverse events usually occurred early, were largely manageable and led to discontinuation in a minority of patients.
Source: Gynecologic Oncology
Authors: Nicoletta Colombo, Kathleen Moore, Giovanni Scambia, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit Oza, Antonio González-Martín, Carol Aghajanian, William H. Bradley, Jae-Weon Kim, Cara Mathews, Joyce Liu, Elizabeth S. Lowe, Ralph Bloomfield, Paul DiSilvestro
Institutions: European Institute of Oncology, OU Health Stephenson Cancer Center, University of Oklahoma, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, UNSW Sydney, Prince of Wales Hospital, City Clinical Oncology Center, Institut Bergonié, Institut Gustave Roussy, The Netherlands Cancer Institute, Edinburgh Cancer Research, University of Edinburgh, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Princess Margaret Cancer Centre, Clinica Universidad de Navarra, Memorial Sloan Kettering Cancer Center, Medical College of Wisconsin, Seoul National University, Women & Infants Hospital of Rhode Island, Dana-Farber Cancer Institute, AstraZeneca (United States), AstraZeneca (United Kingdom)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,900
Funders: AstraZeneca, National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W3190145293
